Category: testosterone for women
AndroFeme 1 included on ARTG for hypoactive sexual desire dysfunction in postmenopausal women
Lawley Pharmaceuticals’ female-specific hormone cream, AndroFeme® 1, has been registered on the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →
AndroFeme 1 licensed for hypoactive sexual desire dysfunction in postmenopausal women
Lawley Pharmaceuticals has obtained approval for registration of AndroFeme® 1 in the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →
Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1
Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →
Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1
Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →
TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction.
TGA accepts AndroFeme 1 for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019 — Lawley Pharmaceuticals today announced AndroFeme 1,… Continue Reading →
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
The Global Consensus Position Statement on the Use of Testosterone Therapy for Women was simultaneously published on the 2nd September 2019 in Maturitas, Journal… Continue Reading →
BBC Menopause and testosterone replacement therapy
Over 900 specialist menopause physicians from around the world attended The European Menopause and Andropause Society conference held in Berlin on 15-17th May 2019. Numerous… Continue Reading →
Effects of testosterone therapy in women – new systematic review and meta-analysis
It has been over a decade since the last systematic review and meta-analysis on the effects of testosterone for women was conducted as an… Continue Reading →
Hypoactive Sexual Desire Disorder (HSDD) re-defined
In late 2018 the World Health Organisation (WHO) released an update to The International Classification of Disease (ICD). ICD is a system of medical coding created… Continue Reading →
FDA acknowledges there is a medical need for treating female sexual dysfunction
In late October 2016 the US FDA released draft guidance for Industry on Low Sexual Interest, Desire, and/or Arousal in Women: Developing Drugs for Treatment. This document states ”… Continue Reading →